Kronos Bio
KRON
KRON was delisted on the 20th of June, 2025.
81 hedge funds and large institutions have $558M invested in Kronos Bio in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 13 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 16
4% more ownership
Funds ownership: 68.84% → 72.84% (+4%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
2% less funds holding
Funds holding: 83 → 81 (-2)
31% less capital invested
Capital invested by funds: $812M → $558M (-$254M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$12.9M |
| 2 |
BlackRock
New York
|
+$6.84M |
| 3 |
Cerity Partners
New York
|
+$6.17M |
| 4 |
AG
Artal Group
Luxembourg
|
+$3.52M |
| 5 |
SG Americas Securities
New York
|
+$2.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$18.8M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$3.84M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.75M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$3.22M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$2.99M |
KRON Hedge Fund Activity: Q4 2021 in Review
81 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Kronos Bio (KRON) for Q4 2021, worth a combined $558M — down 31% from $812M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of KRON and 12 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 30 added.
The largest buyer was State Street, adding an estimated $12.9M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $18.8M sold.
- 81 institutional investors held Kronos Bio (KRON) as of Q4 2021, down from 83 in Q3 2021.
- Funds reported $558M of Kronos Bio stock for Q4 2021, down 31% quarter-over-quarter.
- 12 funds opened new Kronos Bio positions in Q4 2021 and 13 closed out, a net change of -1 holder.
- The largest Kronos Bio buyer in Q4 2021 was State Street, an estimated $12.9M added.
- The largest Kronos Bio seller in Q4 2021 was Capital Research Global Investors, an estimated $18.8M sold.
Based on aggregated 13F filings for Q4 2021.